CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0280 (clinicaltrials.gov NCT No: NCT00429182)
Title:Phase II study of purging of CTCs from Metastatic Breast Cancer Patients
Principal Investigator:Naoto Ueno
Treatment Agent:Carboplatin; Cyclophosphamide; Thiotepa
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the relationship of
high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling
metastatic breast cancer. The study also will investigate the role of CTCs in
breast cancer.

Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:Carboplatin
Cyclophosphamide
Thiotepa
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patient must stay in Houston at least for 6 weeks after transplantation.
Supported By:N/A
Return Visit:As per BMT routine.
Home Care:As per BMT routine.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8754
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults